vs
Side-by-side financial comparison of Sight Sciences, Inc. (SGHT) and WEST BANCORPORATION INC (WTBA). Click either name above to swap in a different company.
WEST BANCORPORATION INC is the larger business by last-quarter revenue ($26.9M vs $20.4M, roughly 1.3× Sight Sciences, Inc.). WEST BANCORPORATION INC runs the higher net margin — 39.2% vs -20.4%, a 59.7% gap on every dollar of revenue. On growth, WEST BANCORPORATION INC posted the faster year-over-year revenue change (16.6% vs 6.9%). WEST BANCORPORATION INC produced more free cash flow last quarter ($12.4M vs $-2.0M). Over the past eight quarters, WEST BANCORPORATION INC's revenue compounded faster (17.3% CAGR vs 2.9%).
Sight Sciences, Inc. is a commercial-stage medical technology company focused on developing and commercializing innovative products for treating common eye conditions including glaucoma and dry eye disease. It offers minimally invasive surgical devices and non-surgical care solutions, primarily serving ophthalmology clinicians and patients across the United States.
West Bancorporation Inc. is a regional financial holding company headquartered in the U.S. Midwest, primarily serving markets across Iowa and Minnesota. It provides a full suite of personal and commercial banking services, including deposit accounts, mortgage loans, business lending, and wealth management solutions for individual consumers, small-to-medium enterprises, and local organizational clients.
SGHT vs WTBA — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $20.4M | $26.9M |
| Net Profit | $-4.2M | $10.6M |
| Gross Margin | 87.3% | — |
| Operating Margin | -18.0% | 50.0% |
| Net Margin | -20.4% | 39.2% |
| Revenue YoY | 6.9% | 16.6% |
| Net Profit YoY | 64.9% | 34.8% |
| EPS (diluted) | $-0.07 | $0.61 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $26.9M | ||
| Q4 25 | $20.4M | $24.2M | ||
| Q3 25 | $19.9M | $25.0M | ||
| Q2 25 | $19.6M | $23.8M | ||
| Q1 25 | $17.5M | $23.1M | ||
| Q4 24 | $19.1M | $20.9M | ||
| Q3 24 | $20.2M | $20.3M | ||
| Q2 24 | $21.4M | $19.6M |
| Q1 26 | — | $10.6M | ||
| Q4 25 | $-4.2M | $7.4M | ||
| Q3 25 | $-8.2M | $9.3M | ||
| Q2 25 | $-11.9M | $8.0M | ||
| Q1 25 | $-14.2M | $7.8M | ||
| Q4 24 | $-11.8M | $7.1M | ||
| Q3 24 | $-11.1M | $6.0M | ||
| Q2 24 | $-12.3M | $5.2M |
| Q1 26 | — | — | ||
| Q4 25 | 87.3% | — | ||
| Q3 25 | 86.4% | — | ||
| Q2 25 | 84.8% | — | ||
| Q1 25 | 86.2% | — | ||
| Q4 24 | 86.8% | — | ||
| Q3 24 | 83.9% | — | ||
| Q2 24 | 85.8% | — |
| Q1 26 | — | 50.0% | ||
| Q4 25 | -18.0% | 39.6% | ||
| Q3 25 | -39.7% | 45.8% | ||
| Q2 25 | -59.6% | 43.4% | ||
| Q1 25 | -79.2% | 43.4% | ||
| Q4 24 | -62.5% | 30.9% | ||
| Q3 24 | -55.7% | 36.6% | ||
| Q2 24 | -59.2% | 32.6% |
| Q1 26 | — | 39.2% | ||
| Q4 25 | -20.4% | 30.7% | ||
| Q3 25 | -41.0% | 37.3% | ||
| Q2 25 | -61.0% | 33.5% | ||
| Q1 25 | -80.8% | 34.0% | ||
| Q4 24 | -62.1% | 34.0% | ||
| Q3 24 | -54.9% | 29.3% | ||
| Q2 24 | -57.7% | 26.5% |
| Q1 26 | — | $0.61 | ||
| Q4 25 | $-0.07 | $0.44 | ||
| Q3 25 | $-0.16 | $0.55 | ||
| Q2 25 | $-0.23 | $0.47 | ||
| Q1 25 | $-0.28 | $0.46 | ||
| Q4 24 | $-0.23 | $0.41 | ||
| Q3 24 | $-0.22 | $0.35 | ||
| Q2 24 | $-0.25 | $0.31 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $92.0M | $362.0M |
| Total DebtLower is stronger | $42.4M | — |
| Stockholders' EquityBook value | $63.9M | $270.7M |
| Total Assets | $115.3M | $4.0B |
| Debt / EquityLower = less leverage | 0.66× | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $362.0M | ||
| Q4 25 | $92.0M | $471.1M | ||
| Q3 25 | $92.4M | $232.9M | ||
| Q2 25 | $101.5M | $345.2M | ||
| Q1 25 | $108.8M | — | ||
| Q4 24 | $120.4M | $243.5M | ||
| Q3 24 | $118.6M | — | ||
| Q2 24 | $118.2M | — |
| Q1 26 | — | — | ||
| Q4 25 | $42.4M | — | ||
| Q3 25 | $42.4M | — | ||
| Q2 25 | $42.4M | — | ||
| Q1 25 | $42.4M | — | ||
| Q4 24 | $40.0M | — | ||
| Q3 24 | $37.1M | — | ||
| Q2 24 | $35.0M | — |
| Q1 26 | — | $270.7M | ||
| Q4 25 | $63.9M | $266.0M | ||
| Q3 25 | $64.3M | $255.1M | ||
| Q2 25 | $70.0M | $240.9M | ||
| Q1 25 | $77.6M | $237.9M | ||
| Q4 24 | $87.5M | $227.9M | ||
| Q3 24 | $95.0M | $235.4M | ||
| Q2 24 | $101.6M | $223.9M |
| Q1 26 | — | $4.0B | ||
| Q4 25 | $115.3M | $4.1B | ||
| Q3 25 | $116.3M | $4.0B | ||
| Q2 25 | $122.0M | $4.1B | ||
| Q1 25 | $129.7M | $4.0B | ||
| Q4 24 | $142.8M | $4.0B | ||
| Q3 24 | $143.6M | $4.0B | ||
| Q2 24 | $149.7M | $4.0B |
| Q1 26 | — | — | ||
| Q4 25 | 0.66× | — | ||
| Q3 25 | 0.66× | — | ||
| Q2 25 | 0.61× | — | ||
| Q1 25 | 0.55× | — | ||
| Q4 24 | 0.46× | — | ||
| Q3 24 | 0.39× | — | ||
| Q2 24 | 0.34× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-1.8M | $12.9M |
| Free Cash FlowOCF − Capex | $-2.0M | $12.4M |
| FCF MarginFCF / Revenue | -9.7% | 46.0% |
| Capex IntensityCapex / Revenue | 0.8% | 1.8% |
| Cash ConversionOCF / Net Profit | — | 1.22× |
| TTM Free Cash FlowTrailing 4 quarters | — | $79.1M |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $12.9M | ||
| Q4 25 | $-1.8M | $46.5M | ||
| Q3 25 | $-8.7M | $11.4M | ||
| Q2 25 | $-7.5M | $13.5M | ||
| Q1 25 | $-11.6M | $9.7M | ||
| Q4 24 | $-3.5M | $39.8M | ||
| Q3 24 | $362.0K | $12.9M | ||
| Q2 24 | $-9.5M | $10.0M |
| Q1 26 | — | $12.4M | ||
| Q4 25 | $-2.0M | $43.2M | ||
| Q3 25 | $-8.9M | $10.8M | ||
| Q2 25 | $-7.8M | $12.8M | ||
| Q1 25 | — | $8.3M | ||
| Q4 24 | $-3.6M | $13.7M | ||
| Q3 24 | $311.0K | $7.0M | ||
| Q2 24 | $-9.5M | $2.7M |
| Q1 26 | — | 46.0% | ||
| Q4 25 | -9.7% | 178.3% | ||
| Q3 25 | -44.7% | 43.0% | ||
| Q2 25 | -39.6% | 53.6% | ||
| Q1 25 | — | 35.7% | ||
| Q4 24 | -18.9% | 65.6% | ||
| Q3 24 | 1.5% | 34.2% | ||
| Q2 24 | -44.7% | 14.0% |
| Q1 26 | — | 1.8% | ||
| Q4 25 | 0.8% | 13.7% | ||
| Q3 25 | 0.9% | 2.6% | ||
| Q2 25 | 1.1% | 3.2% | ||
| Q1 25 | 0.0% | 6.5% | ||
| Q4 24 | 0.7% | 125.3% | ||
| Q3 24 | 0.3% | 29.4% | ||
| Q2 24 | 0.4% | 37.1% |
| Q1 26 | — | 1.22× | ||
| Q4 25 | — | 6.26× | ||
| Q3 25 | — | 1.23× | ||
| Q2 25 | — | 1.70× | ||
| Q1 25 | — | 1.24× | ||
| Q4 24 | — | 5.61× | ||
| Q3 24 | — | 2.17× | ||
| Q2 24 | — | 1.93× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
SGHT
| Surgical Glaucoma | $19.7M | 96% |
| Other | $724.0K | 4% |
WTBA
Segment breakdown not available.
